Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

News

Microdose GLP-1 news

Released: · Last reviewed:

Latest — November 8, 2026

Each item is dated, sourced and marked confirmed or reported.

NexLife microdose plans now cost the same as its standard plans

Re-read on nexlife.us on November 8, 2026, the microdose tirzepatide page prints "$129 all-inclusive" with $125 / $119 / $115 a month on 3 / 6 / 12-month plans, and the microdose semaglutide page "$109 all-inclusive" with $105 / $99 / $95. On October 15 the tirzepatide page showed $189 / $159 / $150 / $147 and the semaglutide page conflicting ladders.

What it means: For cash-pay patients: at NexLife a microdose no longer costs more than a standard plan; the dose your prescriber sets does not change the bill.

Source: nexlife.us microdose program pages · confirmed

Microdose plan prices re-read: Noom Med down to $179, program fees counted

We read seven programs that sell a named microdose plan. Noom Med now charges $179 a month after a $79 first 4-week supply (billed quarterly; $199 in July). Ivím Health prints a $74.99 monthly program fee beside its $133 tirzepatide and $75 semaglutide microdose prices. Lemonaid Health ($199 + $49 membership), AgelessRx, Good Girl Rx and PlexusDx enter our index; Henry Meds prints no microdose price.

What it means: All-in prices run $69 to $248 a month for both drugs; medians $149 (tirzepatide) and $99 (semaglutide).

Source: each program's own page; full report · confirmed

NexLife cuts standard compounded prices

NexLife's standard plans moved to $129 a month month to month for compounded tirzepatide ($125 / $119 / $115 on 3 / 6 / 12 months; $1,380 a year) and $109 for compounded semaglutide ($105 / $99 / $95; $1,140), from $169 and $139.

What it means: Eden Health's $129 tirzepatide (no membership, read October 15) now equals NexLife's month-to-month price; several programs still print lower figures.

Source: nexlife.us plan pages · confirmed

Lilly's third-quarter results: no change seen in Zepbound self-pay prices

After Lilly reported third-quarter results on October 29, the Zepbound savings page (read November 8) and an October 30 archive of the LillyDirect page still list $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg with each refill within 45 days; otherwise $499 or $699). The savings card allows 11 fills a calendar year and ends December 31, 2026.

What it means: Watch for 2027 self-pay terms; current ones end December 31.

Source: zepbound.lilly.com; LillyDirect (archived October 30) · confirmed

Medicare Open Enrollment: what the GLP-1 Bridge does and does not cover

Open Enrollment runs October 15 to December 7, 2026. Per Medicare.gov, the GLP-1 Bridge ($50 for a one-month supply) covers Foundayo, Wegovy and the Zepbound KwikPen only, for people with a BMI of 35 or more, or 30 or 27 or more with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan "might cover" a GLP-1.

What it means: No compounded or microdose product is covered by Medicare.

Source: medicare.gov (read November 8, 2026) · confirmed

Walmart 2027 benefits: diabetes GLP-1s covered, weight-loss GLP-1s still not (CNBC report)

CNBC reports that Walmart will cover Ozempic and Mounjaro at no cost for employees with type 2 diabetes in 2027, after a new prior authorization, but still will not cover Novo or Lilly GLP-1s for weight loss. These details come from news reports, not a Walmart plan document.

What it means: Employer coverage for weight loss remains rare; cash-pay options stay relevant.

Source: CNBC, October 13, 2026 · reported

FDA updates its page on unapproved GLP-1 drugs

FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page (current as of October 1, 2026) includes telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, a warning against semaglutide salt forms, and states that retatrutide and cagrilintide cannot be used in compounding under federal law.

What it means: If your microdose vial lasts longer than 28 days, ask your pharmacy about the discard date.

Source: fda.gov · confirmed

Rhode Island Medicaid ends coverage of GLP-1s prescribed only for weight loss

Under Rhode Island's enacted FY2027 budget, Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss from October 1, 2026; coverage continues for type 2 diabetes and other approved indications.

What it means: Another public payer stepping back from weight-loss coverage.

Source: Rhode Island Medicaid MCO provider notice · confirmed

Medicare GLP-1 Bridge listed through December 31, 2027 on CMS’s BALANCE model page

CMS's BALANCE model page (modified September 29, 2026) lists the Medicare GLP-1 Bridge through December 31, 2027 and carries an FAQ about "the BALANCE Model not launching in Medicare in 2027." Medicare.gov says Bridge prior authorizations are valid through December 31, 2027.

What it means: The $50 Bridge copay remains the Medicare route for eligible people through 2027.

Source: cms.gov · confirmed

FDA warning letter 738238 to Empower Pharmacy

FDA's letter (dated September 18, posted September 22, 2026) says Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions.

What it means: Ask which pharmacy fills your vial; at least one microdose program lists Empower among possible pharmacies.

Source: fda.gov · confirmed

Earlier — August 10, 2026

Every item dated and verified against the publisher’s own pages; the running desk file.

Wegovy pill 4 mg offer ends August 31

NovoCare's published pricing keeps the 1.5 mg oral dose at $149/month but steps the 4 mg dose from $149 to $199 after August 31, 2026 — the entry price of the approved-pill lane shifts in three weeks.

503B exclusion comment window closes; no final rule yet

The FDA's April 30 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list reached the end of its extended comment period on July 30, 2026 (91 FR 38719); as of October 15 no final decision had been published. Finalization would foreclose bulk compounding even in a future shortage; patient-specific 503A prescribing is unaffected.

Brand 12-month subscriptions hold at $249/month

Ro, WeightWatchers, and LifeMD continue the first multi-month brand Wegovy plans launched March 31 — $329/$299/$249 on 3/6/12-month commitments — the narrowest brand-vs-compounded gap on record.

Wegovy HD (7.2 mg) cash price: $399/month

The higher-dose semaglutide approved March 19 (≈20.7% average weight loss in STEP UP) sells through NovoCare at $399/month — $50 over standard pens; the $199 two-fill intro continues through December 31.

Dose-response confirmed at the top: 7.2 mg data

STEP UP quantified the trade: greater weight loss at 7.2 mg with more dose reductions for adverse events (18.5% vs 12.4% at 2.4 mg) and a dysesthesia signal (~1 in 5) — the cleanest evidence yet that effect and tolerability both ride the dose curve.

Tirzepatide–B12 adduct finding keeps additive formulations under scrutiny

2026 laboratory work showing tirzepatide chemically bonds with added vitamin B12 — forming a molecule absent from any approved product — continues to anchor FDA concern about differentiated compounded formulations.

Orforglipron widens the approved oral lane

April's approval of the first oral small-molecule GLP-1 (~12% average loss at top dose, no food/water timing rules) adds a second approved pill and new price pressure below the injectables.

No shortage, no bulk pathway: the supply logic inverts

With both molecules long off the shortage list and the 503B exclusion pending, compounded supply narrows to patient-specific 503A channels — making named pharmacies and month-to-month billing the defensive defaults for any compounded program in 2026.

The full August ledger, in one read →

Seven monitored categories; items publish only when newsworthy and sourced.

Microdose GLP One tracks GLP-1 microdosing developments across seven categories: research, regulation, provider pricing, pharmacy alerts, access and insurance, shortage and supply, and the provider market. Each category publishes an item only when it is genuinely newsworthy and tied to a primary source with a date — we do not manufacture freshness.

Category pages are live as monitored status pages; individual items index only when sourced to a primary record. This avoids fake freshness and soft-404 news shells.

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.